These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 34737227)
21. Usefulness of genetics for clinical reclassification and refinement of prognostic stratification in pulmonary arterial hypertension. Cruz-Utrilla A; Gallego-Zazo N; Pérez-Olivares C; Hernández-González I; Bedate P; Martínez Meñaca A; López Meseguer M; Lapunzina P; Pérez Núñez M; Ochoa Parra N; Valverde D; Tenorio-Castaño JA; Escribano-Subias P Rev Esp Cardiol (Engl Ed); 2023 Jun; 76(6):460-467. PubMed ID: 36403940 [TBL] [Abstract][Full Text] [Related]
22. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience. Deshwal H; Weinstein T; Salyer R; Thompson J; Cefali F; Fenton R; Bondarsky E; Sulica R Ther Adv Respir Dis; 2023; 17():17534666231199693. PubMed ID: 37795626 [TBL] [Abstract][Full Text] [Related]
23. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease]. Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483 [No Abstract] [Full Text] [Related]
24. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Thenappan T; Glassner C; Gomberg-Maitland M Chest; 2012 Mar; 141(3):642-650. PubMed ID: 21885728 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. Ahmed A; Ahmed S; Kempe D; Rådegran G Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867 [TBL] [Abstract][Full Text] [Related]
26. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis. Yogeswaran A; Gall H; Fünderich M; Wilkins MR; Howard L; Kiely DG; Lawrie A; Hassoun PM; Sirenklo Y; Torbas O; Sweatt AJ; Zamanian RT; Williams PG; Frauendorf M; Arvanitaki A; Giannakoulas G; Saleh K; Sabbour H; Cajigas HR; Frantz R; Al Ghouleh I; Chan SY; Brittain E; Annis JS; Pepe A; Ghio S; Orfanos S; Anthi A; Majeed RW; Wilhelm J; Ghofrani HA; Richter MJ; Grimminger F; Sahay S; Tello K; Seeger W; Chest; 2024 Sep; 166(3):585-603. PubMed ID: 38508334 [TBL] [Abstract][Full Text] [Related]
27. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243 [TBL] [Abstract][Full Text] [Related]
28. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012 [TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502 [TBL] [Abstract][Full Text] [Related]
30. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. Rosenkranz S; Pausch C; Coghlan JG; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Delcroix M; Ghofrani HA; Ewert R; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Scelsi L; Neurohr C; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Lange TJ; Olsson KM; Hoeper MM; Opitz C J Heart Lung Transplant; 2023 Jan; 42(1):102-114. PubMed ID: 36333206 [TBL] [Abstract][Full Text] [Related]
31. Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study. Lim Y; Low TT; Chan SP; Teo TW; Jang JJ; Yip N; Kuntjoro I; Tay EL; Yip JW Respirology; 2019 Feb; 24(2):162-170. PubMed ID: 30180305 [TBL] [Abstract][Full Text] [Related]
32. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Frantz RP; Farber HW; Badesch DB; Elliott CG; Frost AE; McGoon MD; Zhao C; Mink DR; Selej M; Benza RL Chest; 2018 Jul; 154(1):126-135. PubMed ID: 29355551 [TBL] [Abstract][Full Text] [Related]
33. Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension. Boucly A; Beurnier A; Turquier S; Jevnikar M; de Groote P; Chaouat A; Cheron C; Jaïs X; Picard F; Prévot G; Roche A; Solinas S; Cottin V; Bauer F; Montani D; Humbert M; Savale L; Sitbon O; Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 38663975 [TBL] [Abstract][Full Text] [Related]
35. Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study. Diez M; Cáneva J; Diez A; Perna ER; Aimone D; Bosio M; Márquez LL; Brasca DG; Vulcano N; Daghero F; Burgos LM; Favaloro L; Escalante JP; Coronel ML; Fernández A; Chávez Á; Secco L; Respir Med Res; 2023 Jun; 83():100945. PubMed ID: 36563553 [TBL] [Abstract][Full Text] [Related]
36. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA; BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059 [TBL] [Abstract][Full Text] [Related]
37. Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension. Prins KW; Kalra R; Rose L; Assad TR; Archer SL; Bajaj NS; Weir EK; Prisco SZ; Pritzker M; Lutsey PL; Brittain EL; Thenappan T J Am Heart Assoc; 2020 Mar; 9(5):e015221. PubMed ID: 32079477 [TBL] [Abstract][Full Text] [Related]
38. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension. Lange TJ Herz; 2023 Aug; 48(4):259-265. PubMed ID: 37085727 [TBL] [Abstract][Full Text] [Related]
39. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan. Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564 [TBL] [Abstract][Full Text] [Related]
40. [Evaluation effect of COMPERA 2.0 risk assessment model on prognosis of Chinese patients with pulmonary arterial hypertension]. Liang YR; Yang YC; Yang BL; Zeng QX; Liu BY; Zhao Q; Luo Q; Zhao ZH; Yang T; Liu ZH; Xiong CM Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1410-1416. PubMed ID: 37150694 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]